Market Herald logo


Be the first with the news that moves the market
  • Purifloh is continuing to face troubles collecting reliable data during its tuberculosis trial
  • The company highlights the issues stem from trial conditions rather than its Free Radical Generator air purification device
  • Shares in the company are trading at $4.91 apiece after a 13.86 per cent drop today

ASX-listed medical company Purifloh has seen its share price suffer today after informing the market of ongoing troubles with its tuberculosis trial.

The company advised it has been unsuccessful in generating reliable baseline data due to issues isolating tuberculosis-causing bacteria from air samples on site.

As a consequence, Purifloh’s share price is down 13.86 per cent, currently sitting at $4.91 apiece, as of 1:34 pm AEST.

Trials testing its Free Radical Generator (FRG) air purification system to eradicate airborne mycobacterium tuberculosis will continue in hospitals despite persistent difficulties.

Difficulties and delays in conducting the trial have been consistent, as outlined across a number of updates by Purifloh this year.

Rapid contamination of the culture by pathogenic molds has continually posed an issue during the trials.

However, according to Purifloh, the troubles in the trials are not due to the function of the FRG device. The company maintains that problems isolating mycobacterium tuberculosis are the cause the issues.

PO3 by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.